Advantage For Synergy’s Plecanatide Over Rival Linzess Holds Up In IBS-C

09 Dec 2016

Plecanatide met the primary endpoint in first Phase III trial in irritable bowel syndrome with constipation, with less incidence of diarrhea than seen in Linzess trials. Synergy is awaiting approval in chronic idiopathic constipation and appears on pace to file an sNDA in IBS-C during the first quarter.

Top-line data for Synergy Pharmaceuticals Inc.’s plecanatide in irritable bowel syndrome with constipation (IBS-C) from the first of two pivotal Phase III trials appears to be confirmation that the guanylyl cyclase C receptor agonist will have the advantage of less incidence of diarrhea than its chief rival, Allergan PLC/Ironwood Pharmaceuticals Inc.’s Linzess.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

17 Apr 2025

• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

Ironwood To Consider All Options With Apraglutide Setback In SBS

14 Apr 2025

• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

14 Apr 2025

• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Compounding Unlikely To Solve GLP-1 Affordable Access Issues

10 Apr 2025

• By Alaric DeArment

The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.